SAN FRANCISCO—Prostate biopsies performed after treatment with 5-alpha reductase inhibitors increase the rate of prostate cancer detection, researchers reported at the American Urological Association annual meeting.

SAN FRANCISCO—Finasteride and dutasteride are similarly effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia in properly selected patients, but dutasteride is associated with significantly greater sexual side effects and breast complications, researchers reported.

They cause fewer UTIs than indwelling catheters in men at high risk during anesthesia and surgery.

The FDA has approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH).

Dual therapy with tamsulosin and dutasteride is more effective than either agent alone in reducing the risk of progression in patients with benign prostatic hyperplasia (BPH), according to the findings of a four-year trial involving 4,800 men who received oral daily tamsulosin (0.4 mg), dutasteride (0.5 mg), or a combination of the two drugs.

Even more than five years postoperatively, the procedure is associated with few complications.

The condition is more likely to develop in men with high interleukin-6 or C-reactive protein levels.

Decreased peak flow rate and a history of hypertension and/or diabetes are significantly associated with CKD in men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), according to investigators in Seoul, Korea.

Dutasteride treatment for benign prostatic hyperplasia (BPH) is associated with a significant increase in serum testosterone and a significant decrease in BMI among men with relatively lower baseline serum testosterone levels, researchers reported in BJU International (2009; published online ahead of print).

A study of 602 Korean men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia found that those with a waist circumference greater than 90 cm (central obesity) had a 36% increased risk of severe LUTS compared with men who had smaller waists.